Percutaneous cryoablation for the treatment of liver cancer at special sites: an assessment of efficacy and safety

Ma, Jun; Wang, Fuming; Zhang, Weiqiang; Wang, Lizhang; Yang, Xiaofeng; Qian, Ying; Huang, Jianjun; Jia, Wang; Yang, Junjie

doi:10.21037/qims.2019.11.12

Cited by 16 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiofrequency ablation (RFA) is the first-line ablation for primary HCC, and the application of RFA in treatment of extrahepatic metastatic HCC to the lung, bone, adrenal glands, and other sites has been reported in previous studies[ 74 , 75 ]. Other ablative modalities, including percutaneous ethanol injection, microwave ablation, laser ablation, and cryoablation, have also been reported being applied in EHM[ 76 - 79 ].…”

Section: Locoregional Therapymentioning

confidence: 99%

Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis

Long

Huang

Xie

et al. 2021

WJCC

View full text Add to dashboard Cite

Extrahepatic metastasis (EHM) of hepatocellular carcinoma (HCC) has increasingly been seen due to improved survival with effective management of intrahepatic lesions. The presence of EHM indicates an advanced stage of HCC, for which systemic therapy serves as the standard treatment modality. Since the approval of Sorafenib as the first systemic agent in 2007, it took almost a decade to show its efficacy in both first and further lines of setting until the landscape of systemic drugs was finally expanded. Moreover, with inspiring results from immunotherapy trials in HCC, it appears that the introduction of immunotherapy may lead to an evolution in the portfolio of HCC treatment. Although the locoregional approach in the management of EHM is not recommended for advanced-stage HCC, efforts have been made to demonstrate its efficacy in symptom relief and potential benefit for overall survival. This review provides a summary of recent updates of the systemic agents in the treatment of advanced HCC, with an emphasis on aggressive locoregional management of EHM by various treatment modalities.

show abstract

Section: Locoregional Therapymentioning

confidence: 99%

Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis

Long

Huang

Xie

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…Local ablative therapy has been applied for symptom palliating in patients with advanced tumors of the lung (80), kidney, bone (81), pancreas, and bile duct (82), as well as liver cancer with a small mass or at special sites where the tumor is directly abutting surrounding structures (such as the liver capsule, gallbladder, vessel, diaphragm, intestine, and adrenal gland), with a maximum distance of 1.0 cm between the tumor and these organs (83). It has also been utilized in the treatment of some benign lesions like osteoid osteomas (84-86), uterine fibroids, Morton's neuroma (87), skin lesions (88), and varicose veins.…”

Section: Ablationmentioning

confidence: 99%

Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment

Fang¹,

Xiao²,

Zhang³

et al. 2021

Quant Imaging Med Surg

View full text Add to dashboard Cite

The Medline and EMBASE databases were searched using (at a minimum) the following keywords: tumor, immunotherapy, interventional therapy, and immunomodulation. All articles studying the immunomodulatory effect of interventional therapy and interventional therapy combined with immunotherapy for tumors were selected by examining their titles or abstracts. After further exploration of the content, articles containing relevant data were then included and summarized. According to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, all selected articles were graded by their level of evidence and strength of recommendation. The literature searches were updated until October 2020.

show abstract

“…Although this method has been less reported than thermal hot ablation techniques, this method has the advantage of being painless during treatment. However, it carries the risk of bleeding and tumor seeding along the needle tract since it cannot be ablated during withdrawal of treatment applicators [20]. Of course, substitution of curative ablation techniques by less invasive out-patient procedure like radio-embolization (SIRT) can also be discussed.…”

Section: Working With Scarce Resources Of General Anesthesiamentioning

confidence: 99%

Interventional oncology at the time of COVID-19 pandemic: Problems and solutions

Denys¹,

Guiu²,

Chevallier³

et al. 2020

Diagnostic and Interventional Imaging

View full text Add to dashboard Cite

The COVID-19 pandemic has deeply impacted the activity of interventional oncology in hospitals and cancer centers. In this review based on official recommendations of different international societies, but also on local solutions found in different expert large-volume centers, we discuss the changes that need to be done for the organization, safety, and patient management in interventional oncology. A literature review of potential solutions in a context of scarce anesthesiologic resources, limited staff and limited access to hospital beds are proposed and discussed based on the literature data.

show abstract

Percutaneous cryoablation for the treatment of liver cancer at special sites: an assessment of efficacy and safety

Cited by 16 publications

References 39 publications

Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis

Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis

Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment

Interventional oncology at the time of COVID-19 pandemic: Problems and solutions

Contact Info

Product

Resources

About